CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11, ...
ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11 ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...
DRI Healthcare Trust (TSX: DHT.UN/DHT.U) ("DRI" or "the Trust") today informs its unitholders of an adjustment to its previously announced quarterly cash distribution to unitholders of record as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback